You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Production of NIST/UCSF Breast Phantom for Magnetic Resonance Imagaing (MRI)

    SBC: Phantom Laboratory            Topic: N/A

    his project involves the commercialization of the breast phantom designed by NIST and University of California, San Francisco (UCSF) for quantitative magnetic resonance imaging (MRI). The breast phantom consists of two independent phantoms, one focused on diffusion MRI measurements and the other focused on accurate measurements of fat and fibroglandular tissue properties. The proposed phantom is o ...

    SBIR Phase I 2014 Department of CommerceNational Institute of Standards and Technology
  2. A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Chronic Pancreatitis (CP) is characterized by continuous or recurrent inflammation of the pancreas that leads to permanent destruction of the pancreas resulting in exocrine and endocrine insufficiency. CP is a common disorder associated with significant morbidity and mortality with an incidence of 8.2 and a prevalence of 27.4 per 100 000 population. The etiolog ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. PRECLINICAL TESTING OF HUMAN GHRELIN AND GROWTH HORMONE FOR SEPSIS IN THE ELDLY

    SBC: THERASOURCE, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The ultimate goal of our proposal is to develop a novel therapeutic approach that will save lives of aged septic patients. Sepsis is the most common cause of death in the non-cardiac intensive care units (ICU). It is particularly a serious problem in the geriatric population. The elderly (e 65 years of age) accounts for 12% of the US population but 65% of sepsi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A biomarker of aging as a predictor of kidney transplant function

    SBC: HEALTHSPAN DIAGNOSTICS, LLC            Topic: NIA

    ABSTRACT The number of kidney transplant candidates on the waiting list continues to increase each year, while the number of kidney donations remains stagnant. The enduring donor shortage compels clinicians to use kidneys from marginal donors, referred toas expanded criteria donors (ECD). ECD kidneys, obtained primarily from older donors, have a higher risk of delayed graft function and graft loss ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes.

    SBC: Mycosynthetix, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Title: Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes Project Summary/Abstract It is estimated that over 2 billion people worldwide are suffering from complications due to infections withsoil transmitted helminthes (STHs), but very little research is being conducted by human health pharmaceutical companies. In the USA, it is estim ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development, Production and Testing of VLP based Respiratory Syncytial Virus (RSV

    SBC: TECHNOVAX INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a safe and efficacious virus-like particle (VLP) based-respiratory syncytial virus (RSV) vaccine to prevent the disease caused by this pathogen. The respiratory illnesses provokedby RSV in infants, children and the elderly are of global economical and public health impact. A recent worldwide estimate [5] indicates that ov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Therapeutic for Radiation Induced Lung Injury

    SBC: Angion Biomedica Corp.            Topic: NIAID

    DESCRIPTION (provided by applicant): Nuclear accidents and terrorism present a serious threat for causing mass-casualty scenarios. In radiation events, many people receive non-uniform whole-body or partial-body irradiation. The risk of exposure to ionizingradiation due to terrorist activities could result in acute injury as well as long-term adverse health effects in thousands of people. The lung ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Biosensor Assays for Diagnosis of Chronic HCV Infection

    SBC: ALDERON BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): This Phase I SBIR application is submitted in response to the call by DHHS for new tests for qualitative measurement of HCV RNA for diagnosis of chronic HCV infection in patients. The need is for HCV RNA assays that areas reliable but less expensive and resource-demanding than current molecular assays. The new test proposed for research and development consists ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Cell analysis and immunoassay device for distributed HIV diagnosis and monitoring

    SBC: INDEXUS BIOMEDICAL, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this research is to develop a new approach to bring diagnosis and monitoring tests for HIV to the primary care level (primary care provider office, small healthcare clinics and labs, and community health center labs) by introducing a multi-functional cell analysis and immunoassay platform that is portable, low cost and easy to use. It will allow pat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil

    SBC: ADJUVANCE TECHNOLOGIES INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Antitumor and anti-infectious disease vaccines require adjuvants in order to obtain optimal immunogenicity and therapeutic and protective efficacy. QS-21 is a natural saponin fraction that significantly out-performs other adjuvants in eliciting productive antibody and T-cell responses. It has remained the adjuvant of choice and has proven it's potency as i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government